Revaccination doses of hepatitis B vaccine for young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective cohort study investigates the optimal revaccination doses of the hepatitis B vaccine for high-risk young adults in Taiwan who lack protective antibodies. Participants aged 20-33, born after 1987, will be grouped based on their antibody levels and receive one or two doses of the vaccine. The study aims to determine the most effective dosing strategy to enhance protection against hepatitis B infection. Participants will be monitored for 12 months to assess their antibody response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The actual age at the time of admission was higher than 20 years old and birth year after 1987
2. Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period.
3. Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline
4. Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire
5. Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process
6. In good health

Exclusion Criteria:

1. Those who were previously allergic to hepatitis B vaccine or its components (such as yeast)
2. Those who have been vaccinated against hepatitis B during childhood and adolescence
3. Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen

Where it's running

• Family Medicine, NTUH
  Taipei, Taipei, Taiwan Recruiting

Study contacts

• Principal investigator: CHYI-FENG JAN, MD, PhD — National Taiwan University Hospital
• Study coordinator: Chyi-Feng Jan, Md, Phd
• Email: jcf036@gmail.com
• Phone: +886-2-23123456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• RSV vaccine safety and immune response in lung transplant patients vs. healthy adults

  This study tests how well the RSV vaccine works and how safe it is in people who have had a lung transplant compared with healthy adults.

  Recruiting Phase 4 Seoul National University Hospital · Seoul, Jongno-Gu · NCT07895394

• Entecavir 0.5 mg vs 1.0 mg daily in adults with HBV-related decompensated cirrhosis

  This trial tests whether 0.5 mg or 1.0 mg of entecavir once daily can better lower HBV DNA in adults with HBV-related decompensated cirrhosis over 24 weeks.

  Recruiting Phase 4 Bangladesh Medical University · Dhaka, Dhaka Division · NCT07816094

• Sleep and Teens’ Immune Response to a Meningococcal Vaccine

  This study checks if 11- to 12-year-olds’ sleep habits affect how well their vaccine for meningococcal disease works.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07636525

• OptiMAx: testing SQ-LNS to boost vaccination in rural Chad and Niger

  This study tests whether giving small-batch SQ-LNS to young children helps increase routine immunizations in rural Chad and Niger.

  Recruiting at 2 sites Alliance for International Medical Action · Ngouri, Lac Region and 1 other locations · NCT07592260

• Hepatitis B in Zambia: an observational cohort of adults with HBV, with or without HIV

  This observational cohort follows adults diagnosed with hepatitis B in Zambia, with and without HIV coinfection, to see how their liver disease and HBV (and HIV when present) change over several years while they receive standard care.

  Recruiting at 3 sites University of Alabama at Birmingham · Lusaka and 2 other locations · NCT07589985

• Using fingerprint-linked digital records and reminders to help children finish their malaria and routine vaccines

  This project will test whether a biometric-linked digital vaccination system plus voice-message reminders can help children in Ghana complete their malaria and routine vaccines.

  Recruiting University of Michigan · Oti Region · NCT07261280

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.